HER2 Low Metastatic Content

HER2 Low Metastatic

Brianna GrahamHER2 Breast Cancer | April 3, 2025

Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends.

Brianna GrahamHER2 Breast Cancer | April 2, 2025

A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.

Brandon TwyfordHER2 Breast Cancer | April 2, 2025

Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.

Leah LawrenceHER2 Breast Cancer | March 31, 2025

The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.

Leah LawrenceHER2 Breast Cancer | March 31, 2025

The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4

Nera Lopetegui-Lia, MDHER2 Breast Cancer | March 31, 2025

Dr. Lopetegui-Lia reacts to Dr. Gatti-Mays' breast cancer panel discussion from Advancements in Oncology.

Dr. Margaret Gatti-MaysHER2 Breast Cancer | March 31, 2025

Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.

Rob DillardHER2 Breast Cancer | March 31, 2025

Dr. Margaret Gatti-Mays talks with The Oncology Brothers about the right treatments for endocrine-resistant breast cancer.